Skip to main content
Population pharmacokinetics of amikacin in neonatal intensive care unit patients
Australasian Medical Journal
  • Paulo Caceres Guido, Garrahan Paediatric Hospital
  • Mónica Travaglianti, Garrahan Paediatric Hospital
  • Graciela Castro, Garrahan Paediatric Hospital
  • Nieves Licciardone, Garrahan Paediatric Hospital
  • Oscar Ferreyra, Garrahan Paediatric Hospital
  • Guillermo Bramuglia, Universidad de Buenos Aires
  • Facundo Garcia Bournissen, Parasitology and Chagas Service - General Hospital of Children R. Gutierrez
  • Paula Schaiquevich, Garrahan Paediatric Hospital
Document Type
Publication Date
URL with Digital Object Identifier

Background Amikacin treatment requires close monitoring of blood concentrations to increase the probability that levels achieved are both effective and safe. Aims We described population pharmacokinetics parameters of amikacin in newborns from a Neonatal Intensive Care Unit with suspected or documented sepsis. Methods A nonlinear mixed-effect model approach was used to analyse the data. Results Twenty seven neonates were enrolled. Final parameter estimates were: Ke(h-1)=0.232x(CR) Exp-0.85; V(mL/kg)=497. Conclusion Weight and serum creatinine are associated with neonatal amikacin volume of distribution and elimination constant rate, respectively. The presence of sepsis may decrease amikacin elimination, although this observation should be further explored. These results could help to individualize amikacin dosage for neonates.

Citation Information
Paulo Caceres Guido, Mónica Travaglianti, Graciela Castro, Nieves Licciardone, et al.. "Population pharmacokinetics of amikacin in neonatal intensive care unit patients" Australasian Medical Journal Vol. 10 Iss. 2 (2017) p. 140 - 144
Available at: